장마감
로그인 회원가입
TLSA
TLSA
Tiziana Life Sciences Ltd
7월 27일 4:00 PM ET (한국 7/28 05:00)
$0.91
+0.02 ▲ +1.98%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$0.94
+0.03 ▲ +3.02%

티지아 라이프 사이언스(TLSA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$117M
스몰캡
P/E
-
배당수익률
없음
52주 위치
3%
저점 +5% · 고점 -65%
애널리스트
적극 매수
F
Fundamental health
vs. 방어주 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 70%
밸류에이션
데이터 부족
재무 안정
Top 87%
Index -P/E -EPS (ttm) -0.16Insider Own 47.35%Shs Outstand 120.5MPerf Week -10.33%
Market Cap 0.12BForward P/E -EPS next Y -Insider Trans -Shs Float 67.6MPerf Month -19.45%
Enterprise Value 0.11BPEG -EPS next Q -Inst Own 2.71%Short Float 1.84%Perf Quarter -29.44%
Income -0.02BP/S -EPS this Y 1.07%Inst Trans 7.68%Short Ratio 5.24Perf Half Y -44.16%
Sales 0.00BP/B 2116.74EPS next 5Y -ROA -161.82%Short Interest 1.25MPerf YTD -38.91%
Book/sh 0P/C 29.12EPS past 3/5Y -0.89% -0.19%ROE -924.32%52W High -64.99% ($2.60)Perf Year -51.06%
Cash/sh 0.03P/FCF -Sales past 3/5Y -ROIC -6444.41%52W Low 5.07% ($0.87)Perf 3Y 34.64%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -40.11%Gross Margin -Volatility(W/M) 15.28% 10.85%Perf 5Y -56.45%
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 0.12Perf 10Y -
Dividend Ex-Date -Quick Ratio 0.76EPS Q/Q -62.78%Profit Margin -RSI (14) 35.26Recom 1
Dividend Gr. 3/5Y -Current Ratio 0.76Sales Q/Q -SMA20 -20.34% ($1.14)Beta 0.52Target Price $9.04
Payout -Debt/Eq 9.2Earnings 2026/06/18SMA50 -25.73% ($1.23)Rel Volume 0.48Prev Close $0.89
Employees 10LT Debt/Eq 4.6EPS/Sales Surpr. -SMA200 -37.69% ($1.46)Avg Volume(3M) 0.24MPrice $0.91
IPO 2018/11/20Option/Short Yes/YesTrades 391Volume 114,375Change 1.98%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Tiziana Life Sciences Ltd (TLSA) Investment Analysis

What kind of company is Tiziana Life Sciences Ltd?

티지아 라이프 사이언스(TLSA) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧬 A clinical-stage immunotherapy developer focused on an intranasal antibody therapy platform, advancing drug candidates for central nervous system diseases such as multiple sclerosis and Alzheimer's. With no commercialized products yet, the company generates no revenue, and as an early-stage biotech, its stock price is heavily influenced by clinical trial results and fundraising activities.

Learn more about Tiziana Life Sciences Ltd →
Market Cap
$0.1B
Approx. KRW 0.2 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank4465
Employees10people
IPO2018/11/20
Current Price$0.91 ≈ 1,247원
NASD · Bermuda

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 6월 18일 (목) · 장 마감 후
🔔 Earnings release 2025년 10월 1일 (수) · 장 마감 후

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-924.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-161.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-6444.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
9.20
✓ Danger level
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
0.76
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.76
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$9.04
현재가 대비 +893.4%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+1.1%
평균
My positionMid-range
Low range Average High range
방어주 초소형주 Median 21.2% · Bottom 33%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-0.9%
부진
My positionBottom 25%
Low range Average High range
방어주 초소형주 Median 30.0% · Bottom 24%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-0.2%
평균
My positionMid-range
Low range Average High range
방어주 초소형주 Median 16.4% · Bottom 33%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -125%p below the market
TLSA -56.5% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-124.8%p
Significantly behind the market
vs Health Care (XLV)
-81.0%p
Significantly behind the sector average
1-year basis
vs S&P 500
-67.1%p
Significantly behind the market
vs Health Care (XLV)
-70.8%p
Significantly behind the sector average
Rank among peers
5-year return Top among peers Based on 245 peers
1-year return Lower-Mid (lower 47%) Based on 315 peers
Current position within 52-week range
Low (-5.1%p) High (-65.0%p)
Current price is 5.1% above the 52-week low and 65.0% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-44.7%
Annualized volatility
79.3%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $0.91 below the midline ($1.14). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.080 < Signal -0.053 in negative zone + Hist negative (-0.027). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 35.5 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 6.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Pricey
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
2116.74x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Biotechnology 초소형주 median 1.35x · Bottom 1% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$9.04 vs. current price +893.4%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Institutional net buying +7.7% · Short interest light 1.8% · Short interest fell -0.6%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+7.7%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 2.7%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 47.4%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 49.9%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.8%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 90 days 📉 -0.6%p decrease
Short interest days to cover
5.2 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 120.5M주
Float (tradable shares) 67.6M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
TLSA TLSA This Stock
$116.8M- 2116.7 -924.32% - +2.0%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 티지아 라이프 사이언스(TLSA)?

티지아 라이프 사이언스(TLSA) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of TLSA?

The market cap of TLSA is approximately $117M, ranking 4,465 within its sector.

What is the 52-week high and low for TLSA?

TLSA has recorded a 52-week high of $2.60 and a low of $0.87.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.